| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |